PMID- 30831650
OWN - NLM
STAT- MEDLINE
DCOM- 20190404
LR  - 20190404
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 48
IP  - 3
DP  - 2019 Mar 8
TI  - [Pathological significance of NY-ESO-1 expression in the diagnosis of myxoid 
      liposarcoma].
PG  - 225-230
LID - 10.3760/cma.j.issn.0529-5807.2019.03.011 [doi]
AB  - Objective: To detect the expression of New York esophageal squamous cell 
      carcinoma antigen 1 (NY-ESO-1) in common types of mesenchymal myxoid tumors, and 
      to investigate its significance in the diagnosis and differential diagnosis of 
      myxoid liposarcoma. Methods: A total of 43 formalin-fixed paraffin-embedded 
      samples of mesenchymal myxoid tumors from the Affiliated Hospital of Qingdao 
      University and Qingdao Municipal Hospital ranging between 2010 and 2017 were 
      selected. NY-ESO-1 expression was detected by immunohistochemical staining. DDIT3 
      gene status was detected by fluorescence in situ hybridization (FISH). NY-ESO-1 
      mRNA was detected by reverse transcription-PCR (RT-PCR). Results: Histopathology 
      and FISH results confirmed that there were 11 cases of myxoid liposarcoma and 32 
      other types (including 7 cases of well-differentiated liposarcoma, 1 
      dedifferentiated liposarcoma, 3 lipomas, 2 lipoblastomas and 19 non-adipocytic 
      tumors). Immunohistochemical staining showed that the positive expression 
      propotion of NY-ESO-1 in myxoid liposarcoma was 11/11, and the positive location 
      was the cytoplasm and nucleus of lipoblast cells. The expression intensity is 
      higher in regions with round cell differentiation. Among the 32 cases of other 
      mesenchymal myxoid tumors, only one well-differentiated liposarcoma showed 
      positive immunoreactivity for NY-ESO-1. RT-PCR confirmed that 7 cases of myxoid 
      liposarcoma (7/11) and one well-differentiated liposarcoma (1/7) had NY-ESO-1 
      mRNA expression. Conclusions: NY-ESO-1 is positively expressed in myxoid 
      liposarcoma. It can be served as a useful marker for the diagnosis and 
      differential diagnosis of myxoid liposarcoma.
FAU - Hei, S M
AU  - Hei SM
AD  - Department of Pathology, School of Basic Medicine, Qingdao University, Qingdao 
      266071, China.
FAU - Wei, H J
AU  - Wei HJ
AD  - Department of Pathology, Qingdao Municipal Hospital, Qingdao 266071, China.
FAU - Chen, H
AU  - Chen H
AD  - Department of Pathology, Qingdao Municipal Hospital, Qingdao 266071, China.
FAU - Wang, J G
AU  - Wang JG
AD  - Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao 
      266003, China.
LA  - chi
GR  - 81502272/National Natural Science Foundation of China/
GR  - 2017M612212/Postdoctoral Science Foundation of China/
GR  - 2017Q12,2017238/Postdoctoral Applied Research Foundation of Qingdao 
      City,"Clinical Medicine+X" Project of Qingdao University/
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CTAG1B protein, human)
RN  - 0 (DDIT3 protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (RNA, Messenger)
RN  - 147336-12-7 (Transcription Factor CHOP)
SB  - IM
MH  - Antigens, Neoplasm/*analysis/genetics
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lipoblastoma/chemistry/pathology
MH  - Lipoma/chemistry/pathology
MH  - Liposarcoma/chemistry/pathology
MH  - Liposarcoma, Myxoid/*chemistry/diagnosis/*pathology
MH  - Membrane Proteins/*analysis/genetics
MH  - RNA, Messenger/analysis
MH  - Transcription Factor CHOP/analysis/genetics
OTO - NOTNLM
OT  - Immunohistochemistry
OT  - In situ hybridization, fluorescence
OT  - Liposarcoma, myxoid
OT  - NY-ESO-1 protein
OT  - Reverse transcriptase polymerase chain reaction
EDAT- 2019/03/05 06:00
MHDA- 2019/04/05 06:00
CRDT- 2019/03/05 06:00
PHST- 2019/03/05 06:00 [entrez]
PHST- 2019/03/05 06:00 [pubmed]
PHST- 2019/04/05 06:00 [medline]
AID - 10.3760/cma.j.issn.0529-5807.2019.03.011 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2019 Mar 8;48(3):225-230. doi: 
      10.3760/cma.j.issn.0529-5807.2019.03.011.